tirzepatide compound for sale Personalized Compounded Treatment Compounded Tirzepatide Injections $100 |

Demand for Novo Nordisks semaglutide drugs and the peptide drugs of its main competitor, Eli Lilly and Company, is tremendous

(about 4.6 pounds)

The programme spans multiple trials targeting distinct endpoints: On 21 May 2026 Eli Lilly reported topline results from TRIUMPH-1, the pivotal Phase 3 obesity trial and the programme's first Phase 3 efficacy readout: in 2,339 adults, mean weight loss at the 80-week primary endpoint reached 19.0% (4mg), 25.9% (9mg), and 28.3% (12mg) versus 2.2% for placebo (Eli Lilly investor release

Blood pressure decreased by an average of 6 mmHg systolic and 3 mmHg diastolic

But roughly 10% to 15% of patients in those trials were nonresponders who lost less than 5% of their body weight